| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Loans > Working Capital - An Effective Tool To Judge Your Company's Efficiency |
|
Top Articles - Working Capital - An Effective Tool To Judge Your Company's Efficiency
Financial management can be divided into asset management, i.e. investments and liabilities, i.e. sources of financing. I According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product t is a common belief that a firm's resource cannot be maximized in the long run unless it survives initial hiccups. It is ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in also common that a firm fails most often because they are unable to meet their working capital needs and as a result, sou lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. nd working capital management is a basic requisite for firm survival. What affects Working Capital Management: Generall here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe organizations are more focused on cash and supply chain issues. On the other hand, external issues like legal environmen d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro or internal matters like organizational structure and information system can significantly influence working capital. D ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ue to market pressure, companies are misled to paying a lot of attention on presenting good quarterly results month after easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi month. Undue focus on this issue may sometimes lead to flattering but inaccurate picture of working capital performance. nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically Measures to improve Working Capital: Proper cash flow forecasting is the main issue of effective working capital manage and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ent. This should take into account the impact of unforeseen events, market cycles, loss of customers and strategies taken ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi by competitors. The effect of unforeseen demands on working capital should be factored in. There are certain advantages ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a of working capital on a corporate basis. Cash generated at one location can be well used at another. For this to happen e dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod fectively, good linkages between production and billing, internal flow of cash and sound treasury practices should be in cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin place. Executives at the highest levels should rightly set the target and performance levels. This is necessary and will tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen help in identifying and implementing strategies generating short-term cash. Dispute management system in a company shoul t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel be effective especially in relation to customers. This is needed in freeing up cash otherwise locked due to disputes. It ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust will also improve customer relation and free up legitimate activities like sales and cash collection. So, y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products w" href="http://www.cashdirectone.com">working capital is an important tool to measure a company's operational and fi . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de nancial efficiency. This aspect must be incorporated in the company's strategic and operational thinking. Efforts should elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip lways be made to improve company's working capital, which in the long run, would grow into a better customer relationship tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:How To Lower Your Advertising Budget And Increase Results At The Same Time Customer Loyalty is the Very Fibre of Your Business
|